PMV Pharmaceuticals, Inc.: appoints director Matthew Eckler

What happened

• The company announced that Dr. Matthew Eckler was appointed to the board of directors on Oct 1, 2026. His term of office expires at the company’s 2029 annual meeting of stockholders.
• Dr. Eckler, age 42, has served as a Principal at Samsara BioCapital, LLC since May 2025 and was a healthcare investor at ArrowMark Partners from May 2021 to May 2025. He holds a B.S. in Biology from the University of North Carolina at Chapel Hill, a Ph.D. in Molecular Biology from the University of California, Santa Cruz, and completed a postdoctoral fellowship in neuroscience at the University of California, San Diego.

Key details

• Appointment date: Oct 1, 2026; term expires at the 2029 annual meeting of stockholders.
• Director compensation: eligible for $40,000 in annual cash compensation plus additional cash for committee service.
• Equity awards: initial stock option award for 84,000 shares granted on the first trading date on or after the appointment; annual option to purchase 42,000 shares effective on the date of each annual meeting.
• The company entered into its standard form of indemnification agreement with Dr. Eckler and reported no arrangements or family relationships requiring disclosure under Item 404(a) of Regulation S-K.

Why it may matter

• This Form 8-K reports an Item 5.02 director appointment and, under Item 7.01, furnishes a press release dated Oct 5, 2026 announcing the appointment. It also reports director compensation arrangements under the company’s outside director compensation policy. The filing lists an exhibit containing the press release and an Inline XBRL cover page.
• The filing does not show why the insider traded or why the company acted.